Ahuva Averin

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Top Venues

Infectious diseases and therapy

Expert review of vaccines

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen, Dhwani Hariharan, Mark Atwood, Carolina Carballo, Liping Huang
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Infectious diseases and therapy 13 (6) (2024)
Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen, Dhwani Hariharan, Mark Atwood, Carolina Carballo, Liping Huang
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Infectious diseases and therapy 13 (6) (2024)
Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen, Dhwani Hariharan, Mark Atwood, Carolina Carballo, Liping Huang
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Infectious diseases and therapy (2024)
Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen, Dhwani Hariharan, Mark Atwood, Carolina Carballo, Liping Huang
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Infectious diseases and therapy 13 (6) (2024)
Diana Mendes, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary P E Slack, Gillian F Ellsbury, Tendai Mugwagwa
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert review of pharmacoeconomics & outcomes research 22 (8) (2022)
Tendai Mugwagwa, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary P E Slack, Gillian F Ellsbury, Diana Mendes
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. Expert review of vaccines 21 (9) (2022)